All In MedTech

Device Trial Radar · NCT06803927

Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples

Non-Endoscopic Detection of Barrett's Esophagus and Esophageal Neoplasia Using Methylation Biomarkers on Endosign® Cell Collection Device Samples

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Feb 5, 2025

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Cyted Health IncNot on our public-company list
Sponsor type
Industry
First posted
Jan 31, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is looking at cells collected from the esophagus using a diagnostic device called the EndoSign® Cell Collection Device (a sponge on a thread). Subjects swallow a capsule, which dissolves in the stomach and releases a sponge that collects cells from the esophagus as the sponge is withdrawn using the thread. These cells will be tested to check for a condition called "Barrett's Esophagus." The cells from the sponge will be tested using Cyted Health biomarkers and compared to the results from a regular endoscopy and any biopsies that are taken. To do this, we need sponge samples from people who might have Barrett's Esophagus based on their risk factors, and from people with Barrett's Esophagus. Subjects will have one visit to have the Endosign Cell Collection Device administered prior to having a standard of care endoscopy. They will answer some questions about their medical history and experience with the cell collection procedure as part of the study. Data will be collected from medical records including post-endoscopy.

Conditions

  • Barrett Esophagus

Interventions

  • Barrett's Esophagus Test (LDT)Device

    Barrett's Esophagus Test (LDT) will be performed on esophageal cells collected using the EndoSign Cell Collection Device (510(k) cleared) and compared to the results of standard of care EGD plus biopsies (if applicable)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance of Barrett's Esophagus Test (LDT) compared to standard of care.Time frame: Sample collection prior to standard of care endoscopy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gastroenterology Practice

    Cordova, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.